IN2013MU01468A - - Google Patents

Info

Publication number
IN2013MU01468A
IN2013MU01468A IN1468MU2013A IN2013MU01468A IN 2013MU01468 A IN2013MU01468 A IN 2013MU01468A IN 1468MU2013 A IN1468MU2013 A IN 1468MU2013A IN 2013MU01468 A IN2013MU01468 A IN 2013MU01468A
Authority
IN
India
Prior art keywords
compound
formula
fatty liver
nonalcoholic
liver
Prior art date
Application number
Inventor
Pankaj Patel
Jani Rajendrakumar Hariprasad
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2013387996A priority Critical patent/AU2013387996B2/en
Priority to BR112015020600A priority patent/BR112015020600A2/en
Priority to CN201380075905.9A priority patent/CN105377246B/en
Priority to MA38385A priority patent/MA38385A1/en
Priority to PCT/IN2013/000391 priority patent/WO2014174524A1/en
Priority to US14/782,609 priority patent/US20160166539A1/en
Priority to IN1468MU2013 priority patent/IN2013MU01468A/en
Priority to EA201592020A priority patent/EA201592020A1/en
Priority to JP2016505927A priority patent/JP6246895B2/en
Priority to CA2900435A priority patent/CA2900435C/en
Priority to SG11201506218UA priority patent/SG11201506218UA/en
Priority to GEAP201313941A priority patent/GEP201706663B/en
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to UAA201509744A priority patent/UA114360C2/en
Priority to KR1020157024370A priority patent/KR101617812B1/en
Priority to AP2015008674A priority patent/AP2015008674A0/en
Priority to MX2015010769A priority patent/MX346943B/en
Priority to EP13767126.9A priority patent/EP2988736A1/en
Priority to MYPI2015002026A priority patent/MY180160A/en
Publication of IN2013MU01468A publication Critical patent/IN2013MU01468A/en
Priority to IL240183A priority patent/IL240183A/en
Priority to PH12015501795A priority patent/PH12015501795A1/en
Priority to HK16103017.5A priority patent/HK1214968A1/en
Priority to IL247231A priority patent/IL247231A/en
Priority to US15/343,859 priority patent/US9814697B2/en
Priority to US15/801,738 priority patent/US20180185330A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein 'R' is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).
IN1468MU2013 2013-04-22 2013-06-25 IN2013MU01468A (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
UAA201509744A UA114360C2 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
BR112015020600A BR112015020600A2 (en) 2013-04-22 2013-06-25 pharmaceutical composition, method for treating and / or ameliorating non-alcoholic liver fat disease and use of the composition
KR1020157024370A KR101617812B1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease
PCT/IN2013/000391 WO2014174524A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
US14/782,609 US20160166539A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
IN1468MU2013 IN2013MU01468A (en) 2013-04-22 2013-06-25
EA201592020A EA201592020A1 (en) 2013-04-22 2013-06-25 NEW COMPOSITION FOR NONALCOHOLIC FATIAL LIVER DISEASE (NAFLD)
JP2016505927A JP6246895B2 (en) 2013-04-22 2013-06-25 Novel composition for non-alcoholic fatty liver disease (NAFLD)
CA2900435A CA2900435C (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
SG11201506218UA SG11201506218UA (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
GEAP201313941A GEP201706663B (en) 2013-04-22 2013-06-25 Novel composition for nonalcoholic fatty liver disease (nafld
AU2013387996A AU2013387996B2 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (NAFLD)
CN201380075905.9A CN105377246B (en) 2013-04-22 2013-06-25 For non-alcohol fatty liver (NAFLD) new compositions
MA38385A MA38385A1 (en) 2013-04-22 2013-06-25 New composition for non-alcoholic fatty liver disease (nafld)
AP2015008674A AP2015008674A0 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (NAFLD)
MX2015010769A MX346943B (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld).
EP13767126.9A EP2988736A1 (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
MYPI2015002026A MY180160A (en) 2013-04-22 2013-06-25 A novel composition for nonalcoholic fatty liver disease (nafld)
IL240183A IL240183A (en) 2013-04-22 2015-07-28 Composition for nonalcoholic fatty liver disease (nafld)
PH12015501795A PH12015501795A1 (en) 2013-04-22 2015-08-14 A novel composition for nonalcoholic fatty liver disease (nafld)
HK16103017.5A HK1214968A1 (en) 2013-04-22 2016-03-15 A novel composition for nonalcoholic fatty liver disease (nafld) (nafld)
IL247231A IL247231A (en) 2013-04-22 2016-08-11 Composition for treating non-alcoholic fatty liver disease (nafld)
US15/343,859 US9814697B2 (en) 2013-04-22 2016-11-04 Composition for nonalcoholic fatty liver disease (NAFLD)
US15/801,738 US20180185330A1 (en) 2013-04-22 2017-11-02 Novel composition for nonalcoholic fatty liver disease (nafld)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1468MU2013 IN2013MU01468A (en) 2013-04-22 2013-06-25

Publications (1)

Publication Number Publication Date
IN2013MU01468A true IN2013MU01468A (en) 2015-04-17

Family

ID=49253372

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1468MU2013 IN2013MU01468A (en) 2013-04-22 2013-06-25

Country Status (21)

Country Link
US (3) US20160166539A1 (en)
EP (1) EP2988736A1 (en)
JP (1) JP6246895B2 (en)
KR (1) KR101617812B1 (en)
CN (1) CN105377246B (en)
AP (1) AP2015008674A0 (en)
AU (1) AU2013387996B2 (en)
BR (1) BR112015020600A2 (en)
CA (1) CA2900435C (en)
EA (1) EA201592020A1 (en)
GE (1) GEP201706663B (en)
HK (1) HK1214968A1 (en)
IL (2) IL240183A (en)
IN (1) IN2013MU01468A (en)
MA (1) MA38385A1 (en)
MX (1) MX346943B (en)
MY (1) MY180160A (en)
PH (1) PH12015501795A1 (en)
SG (1) SG11201506218UA (en)
UA (1) UA114360C2 (en)
WO (1) WO2014174524A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009136A1 (en) 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
UA114360C2 (en) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед A novel composition for nonalcoholic fatty liver disease (nafld)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (en) 2013-07-05 2016-10-16 卡地拉保健有限公司 Synergistic compositions
IN2013MU02470A (en) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
US20180243263A1 (en) * 2016-12-09 2018-08-30 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
PL3600309T3 (en) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
GB201710229D0 (en) * 2017-06-27 2017-08-09 Tdeltas Ltd Compounds for new use
TWI814744B (en) * 2017-10-06 2023-09-11 美商基利科學股份有限公司 Combination therapy comprising an acc inhibitor
CN109675016A (en) * 2017-10-18 2019-04-26 上海贺普药业股份有限公司 The therapeutic agent of non-alcohol fatty liver
CN110934866B (en) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 Use of sitagliptin carboxylic acids and related compounds
US20220071954A1 (en) * 2018-12-18 2022-03-10 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma
US20220175721A1 (en) * 2019-02-13 2022-06-09 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2022246243A1 (en) * 2021-05-21 2022-11-24 HepQuant, LLC Methods of defining functional change and slowing progression in chronic liver disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (en) 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
NZ253742A (en) 1992-07-03 1997-06-24 Smithkline Beecham Plc Heterocyclylaminoalkoxy substituted phenyl derivatives and pharmaceutical compositions
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (en) 1994-07-29 1997-11-25 Smithkline Beecham Plc Compound process for the preparation of the same pharmaceutical composition processes for the treatment and / or prophylaxis of hyperglycemia in a human or non-human mammal and for the treatment of hyperlipidemia hypertension cardiovascular disease some eating disorders the treatment and / or prophylaxis of kidney disease prevention revers o stabilization or retardation of microalbuminuria progression in a human or non-human mammal use of the compound and intermediate compound
WO1996033998A1 (en) 1995-04-28 1996-10-31 Daiichi Pharmaceutical Co., Ltd. Pentacyclic compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
AU1198699A (en) 1997-10-27 1999-04-23 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP1082313A1 (en) 1998-05-27 2001-03-14 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU6325799A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
ES2449194T3 (en) 2000-01-19 2014-03-18 Cadila Healthcare Limited Compounds that have hypolipidemic and hypocholesterolemic activities, procedure for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
CN102079743B (en) 2004-03-15 2020-08-25 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
EA200800869A1 (en) * 2005-09-19 2008-10-30 ДЖОНСОН ЭНД ДЖОНСОН ФАРМАСЬЮТИКАЛ РИСЕРЧ ЭНД ДИВЕЛОПМЕНТ, Эл. Эл. Си. MODULATION OF THE GLUCAGON RECEPTOR EXPRESSION
JP5431940B2 (en) * 2006-09-18 2014-03-05 アルナイラム ファーマシューティカルズ， インコーポレイテッド RNAi regulation of SCAP and its therapeutic use
JP2008184429A (en) * 2007-01-30 2008-08-14 Japan Health Science Foundation Liver triglyceride concentration-lowering agent
CN102647982B (en) 2009-11-26 2014-10-15 基恩菲特公司 Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
RU2013121270A (en) 2010-10-12 2014-11-20 Серекор Инк. COMPOUNDS AGAINST COUGH CONTAINING MEMANTINE
EP3009136A1 (en) * 2011-01-31 2016-04-20 Cadila Healthcare Limited Treatment for lipodystrophy
UA114360C2 (en) 2013-04-22 2017-05-25 Каділа Хелткере Лімітед A novel composition for nonalcoholic fatty liver disease (nafld)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (en) 2013-07-05 2016-10-16 卡地拉保健有限公司 Synergistic compositions
IN2013MU02470A (en) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
EP3039011A1 (en) 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
US10112898B2 (en) 2013-09-06 2018-10-30 Cadila Healthcare Limited Process for the preparation of saroglitazar pharmaceutical salts

Also Published As

Publication number Publication date
IL240183A0 (en) 2015-09-24
WO2014174524A1 (en) 2014-10-30
AU2013387996B2 (en) 2015-12-10
US9814697B2 (en) 2017-11-14
MX2015010769A (en) 2015-11-26
WO2014174524A8 (en) 2015-10-01
KR20150118990A (en) 2015-10-23
EP2988736A1 (en) 2016-03-02
GEP201706663B (en) 2017-05-10
EA201592020A1 (en) 2016-05-31
HK1214968A1 (en) 2016-08-12
CN105377246A (en) 2016-03-02
UA114360C2 (en) 2017-05-25
IL240183A (en) 2016-08-31
CN105377246B (en) 2018-03-20
IL247231A (en) 2017-03-30
PH12015501795A1 (en) 2015-11-09
JP2016515608A (en) 2016-05-30
US20160166539A1 (en) 2016-06-16
CA2900435A1 (en) 2014-10-30
MA38385A1 (en) 2017-09-29
MY180160A (en) 2020-11-23
US20180185330A1 (en) 2018-07-05
BR112015020600A2 (en) 2017-07-18
SG11201506218UA (en) 2015-09-29
KR101617812B1 (en) 2016-05-03
AP2015008674A0 (en) 2015-08-31
US20170087127A1 (en) 2017-03-30
CA2900435C (en) 2017-02-14
MX346943B (en) 2017-04-06
AU2013387996A1 (en) 2015-09-24
JP6246895B2 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
PH12015501795A1 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
EA032971B1 (en) Berberine and ursodeoxycholic acid salt and application thereof
MX360979B (en) Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
NZ726366A (en) Syk inhibitors
MX349159B (en) Deuterated derivatives of ivacaftor.
MX365950B (en) Pyridazinone compounds and methods for the treatment of cystic fibrosis.
MY178621A (en) Deuterated cftr potentiators
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
MX2015004771A (en) Methods of treating cancer.
MX2014000130A (en) Methods and compositions for inhibition of bone resorption.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
TN2015000293A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
BR112013021566A2 (en) compound of formula, or a pharmaceutically acceptable salt or adduct thereof and method of preventing and / or treating an individual comprising administering to said individual a therapeutically effective amount of a compound of formula
PH12016502352A1 (en) Pharmaceutical composition
BR112016024020A2 (en) pharmaceutical composition
MX2012012095A (en) Thiazolidinedione analogues.
BR112019005456A2 (en) pharmaceutical composition and method for treating nonalcoholic hepatic steatosis
MX2015012455A (en) Method for the treatment of fatty liver disease.
MX2019002579A (en) Compositions and methods of use of gamma-ketoaldehyde scavengers for treating, preventing or improving nonalcoholic fatty liver disease (nafld), nash, ald or conditions related to the liver.
EA201291384A1 (en) THERAPEUTIC AGENTS 976
PH12016501553B1 (en) Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations
NZ701995A (en) Therapeutic biologic for treatment of hepatocellular carcinoma